Since its advent in 2011, cancer immunotherapy has led to complete remission in some patients. A multi-institutional study found that mIHC/mIF had higher predictive accuracy than PD-L1 IHC and genomic biomarkers. The study also found that multimodal approaches have lower or similar predictive values as mIHC/mIF-based biomarkers.


There’s a need for better biomarkers to predict who will respond to treatment and improve patient care. But average response rates continue to remain in the 20 to 30% range.

There’s a need for better biomarkers to predict who will respond to treatment and improve patient care. But average response rates continue to remain in the 20 to 30% range.

Better Predictive Capabilities and Reproducibility

Multimodal approaches have lower or similar predictive values compared to single-modal approaches.

Better Predictive Capabilities and Reproducibility

Multimodal approaches have lower or similar predictive values compared to single-modal approaches.

Comprehensive Multiplex Immunofluorescence Solutions for Spatial Phenotyping

In the world of cancer biology, context matters. Akoya offers whole slide imaging solutions with single cell resolution empowering you to discover novel signatures in the tumor microenvironment.

Learn more at akoyabio.com/sps

References